SNDX 6352

Drug Profile

SNDX 6352

Alternative Names: Anti-CSF-1R monoclonal antibody - Syndax Pharmaceuticals; SNDX-6352; UCB 6352

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Developer Syndax Pharmaceuticals; UCB
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 05 Mar 2018 Syndax Pharmaceuticals initiates a multiple ascending dose phase I trial for Solid tumours
  • 01 Feb 2018 Syndax Pharmaceuticals plans a phase Ib trial for Solid tumours (Combination therapy) in the first half of 2018
  • 01 Feb 2018 Syndax Pharmaceuticals enters into a clinical trial collaboration with AstraZeneca for Solid tumours (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top